Brazilian Society of Rheumatology's fibromyalgia treatment guidelines - part I: monitoring and non-pharmacological management
Abstract
Fibromyalgia is one of the most prevalent rheumatologic conditions, affecting millions of individuals worldwide. It is characterized by widespread chronic pain accompanied by symptoms such as fatigue, sleep disturbances, and cognitive impairments. In Brazil, fibromyalgia is the second most common rheumatologic disorder, with a reported prevalence ranging from 2.5% to 5.5%, leading to a substantial economic burden due to high direct and indirect healthcare costs. The pathophysiology of fibromyalgia involves alterations in central pain processing, often in conjunction with comorbidities such as depression, anxiety, and irritable bowel syndrome, which exacerbate symptom severity and negatively impact patients’ quality of life. Effective management requires a structured, interdisciplinary approach that emphasizes treatment adherence and patient education. This guidelines from the Brazilian Society of Rheumatology (SBR) provide an updated review of the 2010 recommendations, incorporating recent evidence to refine both pharmacological and non-pharmacological therapeutic strategies, and are presented in two separate articles, covering aspects of patient monitoring, non-pharmacological interventions, and pharmacological treatments. This approach underscores commitment to comprehensive, evidence-based, and patient-centered care. This first article focuses on the evaluation of monitoring strategies and non-pharmacological interventions for managing fibromyalgia.Fibromyalgia is one of…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.